Special

Big business Bioprocessing

The expansion of global biomanufacturing capacity has been the dominant topic not only since the approval of the most successful biotech drug of all time, Pfizer/BioNTech's mRNA-based COVID-19 vaccine Comirnaty.

In this issue:

  • Mastering the data revolution of clinical trials
  • Lead optimisation – the sequence is the key
  • Automating patient-derived cell production – Interview with Nabiha Sakalyen, CEO & co-founder of Cellino Biotech Inc.
  • A new purification workflow
  • RTSM benefits: configuration vs. customisation

Marketing Contacts:

Andreas Macht
Tel: +49-30-264921-54
a.macht(at)biocom.de

Oliver Schnell
Tel: +49-30-264921-45
o.schnell(at)biocom.de

Editorial Contact:

Thomas Gabrielczyk
Tel: +49-30-264921-50
t.gabrielczyk(at)biocom.de